logo
Share SHARE
FONT-SIZE Plus   Neg

Reports: HSBC Unlikely To Take Part In UK Government's Lending Scheme

HSBC Holdings Plc (HBC,HSBA.L) is unlikely to partcipate in a lending scheme envisaged by the UK government to disburse loans to small firms at reduced rates, reports said.

The National Loan Guarantee Scheme is a major component of the credit-easing program that Chancellor of the Exchequer George Osborne announced last year. Its objective is to increase the flow of credit to small and medium businesses by lowering borrowing costs to banks and companies.

Banking giants Barclays Plc, Lloyds Banking Group and Royal Bank of Scotland, along with start-up Aldermore are expected to join the program when it is launched on Tuesday.

The participating banks will have access to cheap funding from the government and the lower costs are to be passed on to customers. However, many major banks already have access to cheap credit from financial markets and Barclays is said to have reservations about the scheme.

It is reported that the scheme will not enable HSBC to lend any cheaper than it is currently doing and the lender still gets a profit on these.

HSBA.L closed on Friday at 580.40 pence, up 5.60 pence or 0.97 percent, on a volume of 49.63 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Hyundai Motor America, an official NFL sponsor, is returning to Super Bowl advertising, and planning to shoot a documentary as the game is being played to run in its spot. The reigning 2016 USA Today Super Bowl Ad Meter winner, in a statement on Wednesday, said it will film a 90-second documentary during the game that will capture some of the best off-the-field Super Bowl moments. Consumer Financial Protection Bureau or CFPB filed a lawsuit Wednesday against Navient, the nation's largest student loan company, alleging that it failed borrowers at at every stage of repayment. In response, Navient, in a statement, said the allegations are unfounded, and with political motivations, and rejected CFPB ultimatum to settle by Inauguration Day or be sued. Lilly is all set to acquire CoLucid Pharma for $46.50 per share in cash or approximately $960 million.
comments powered by Disqus
Follow RTT